Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965339 | 0.85 | HRH3 (0.53) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL17557724 | 0.84 | HRH3 (0.51) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL2164745 | 0.82 | CA12 (0.63) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL13073181 | 0.80 | ITGB3 (0.55) | ITGB3ITGA2B | |
| SCHEMBL26961928 | 0.79 | ITGB3 (0.58) | CA12CA1CA2CA9ITGB3 | |
| Trifluoroacetic Acid SCHEMBL7542153 | 0.78 | MAPT (0.62) | CA12CA1CA2CA9 | |
| SCHEMBL9936939 | 0.78 | CA12 (0.48) | CA12CA1CA2CA9ITGB3 | |
| Hydrochloric Acid SCHEMBL29796753 | 0.77 | ITGB3 (0.56) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7420441 | 0.77 | FFAR1 (0.60) | PPARGPPARA | |
| Trifluoroacetic Acid SCHEMBL668082 | 0.76 | CA12 (0.56) | CA12CA1CA2CA9ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-2651454-A1 | IMAGING AGENTS | Chroma Therapeutics Ltd. (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080705-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010762-A1 | IMAGING AGENTS | CES1, CES2, NCEH1 | CA12 211/4885CA1 50/4885CA2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.